Spain Vaccines Market Overview, 2028

Spain has made significant strides in vaccine development and usage, driven by its commitment to public health and a thriving pharmaceutical and biotechnology sector. The country has actively engaged in research and development, vaccine production, and vaccination campaigns, with various government associations and organizations playing key roles. The Spanish government is instrumental in promoting vaccine development and usage. The Ministry of Health, Consumer Affairs, and Social Welfare (Ministerio de Sanidad, Consumo y Bienestar Social) formulates vaccination policies, sets guidelines, and coordinates national vaccination campaigns. Under its leadership, Spain has established an efficient and comprehensive vaccination program, covering a wide range of preventable diseases, from childhood immunizations to vaccinations for adults and the elderly. The Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) oversees the authorization and regulation of vaccines in Spain. It ensures that vaccines meet rigorous safety and efficacy standards before they are approved for use, instilling confidence in the public regarding vaccine safety. Spain is also home to several pharmaceutical and biotechnology companies that contribute to vaccine development. Notably, the Spanish company, Rovi, has played a crucial role in the production of vaccines, including the manufacturing of Moderna's COVID-19 vaccine. This reflects Spain's growing capabilities in vaccine production, bolstering the country's self-sufficiency and contributing to the global supply of vaccines. In terms of vaccine usage, Spain has a robust vaccination coverage rate, thanks to its well-established healthcare system and public awareness campaigns. The Autonomous Communities, which have healthcare powers, implement vaccination programs at the regional level, following the national guidelines. According to the research report, “Spain Vaccine Market Overview, 2028” published by Bonafide Research, the Spain Vaccine market is anticipated to add more than USD 500 Million from 2023 to 2028. The vaccine usage market in Spain is experiencing significant growth, underpinned by several key factors that reflect the country's commitment to public health, advancements in medical research, and an increasingly vaccine-aware population. Spain's robust vaccination programs have been instrumental in driving the growth of the vaccine usage market. The government's commitment to preventing infectious diseases through immunization has resulted in comprehensive vaccination schedules for various age groups. These programs ensure that a wide range of vaccines, including those for childhood diseases, influenza, and emerging health threats. Spain's thriving pharmaceutical and biotechnology sector also plays a pivotal role in the growth of the vaccine usage market. The country is home to companies involved in vaccine development and production, contributing not only to domestic immunization efforts but also to the global supply of vaccines. Collaborations with international vaccine manufacturers have expanded Spain's capacity to produce and distribute vaccines, fostering self-sufficiency and economic growth. Moreover, public awareness and trust in vaccines have increased, driven by both government initiatives and healthcare professionals' efforts. Organizations like the Spanish Pediatric Association (AEP) and the Spanish Association of Vaccinology (AEV) provide expert guidance and recommendations, bolstering public confidence in vaccination. Spain's healthcare infrastructure, characterized by well-trained healthcare professionals and accessible healthcare facilities, further supports the growth of the vaccine usage market. Vaccination campaigns are efficiently executed, ensuring high coverage rates across the country.

In Spain, as in many other countries, the choice of vaccine technology depends on the specific pathogen (bacteria or virus) being targeted and the market dynamics reflect this diversity. Among the various vaccine technologies available, conjugate vaccines have gained significant prominence in the Spanish market. Conjugate vaccines are particularly valuable in combating bacterial infections, especially those caused by bacteria with polysaccharide capsules, such as Streptococcus pneumoniae and Haemophilus influenzae type B. These vaccines combine a weak antigen from the pathogen with a carrier protein, enhancing their effectiveness, especially in vulnerable populations like infants and young children. The robust immune response elicited by conjugate vaccines has made them instrumental in preventing serious diseases like pneumonia and meningitis. The preference for conjugate vaccines in Spain may be attributed to the country's commitment to comprehensive immunization programs, with a focus on protecting public health, particularly in the pediatric population. The success of these programs in reducing the burden of vaccine-preventable diseases has likely contributed to the market dominance of conjugate vaccines. In the Spanish vaccine market, the segmentation based on the route of vaccine administration is a key factor in determining the accessibility and effectiveness of vaccination strategies. This segmentation primarily includes three main categories: Intramuscular and Subcutaneous Administration, Oral Administration, and Others encompassing various alternative methods. Intramuscular and subcutaneous administration methods involve injecting the vaccine into the muscle or the subcutaneous tissue beneath the skin. These routes are commonly used for a variety of vaccines, including those targeting diseases like influenza, measles, and hepatitis. They are well-established, widely accepted, and often preferred for certain vaccines that require a deeper delivery to stimulate a strong immune response. Oral administration of vaccines is particularly valuable, as it offers a non-invasive and patient-friendly approach, especially for children. The ease of administration can contribute to higher vaccination rates and better compliance. In Spain, oral vaccines have been instrumental in preventing diseases like rotavirus and polio. The convenience of oral administration aligns with Spain's commitment to comprehensive vaccination programs, especially in pediatric care. The category of "Others" encompasses a diverse range of administration methods, including intradermal, nasal, intravenous, transdermal patches, oral-mucosal vaccines, microneedle patches, jet injectors, intraperitoneal administration, intranasal droplets, and more. These methods may be employed for specific vaccines targeting particular diseases or populations. Spain's vaccination strategy reflects a commitment to delivering vaccines effectively and efficiently, adapting to the unique requirements of each vaccine and target population. This approach not only ensures broad coverage against a wide range of diseases but also accommodates patient preferences and healthcare infrastructure considerations. It highlights the flexibility and adaptability of Spain's vaccination efforts to meet the diverse needs of its population, ultimately contributing to public health and disease prevention. By the Type of Vaccines, the market is segmented into Multivalent and Monovalent Vaccines. To protect effectively, some vaccines require multiple antigens of one pathogen or different pathogen serotypes/serogroups in combination (multivalent or polyvalent vaccines). Multivalent vaccines and monovalent vaccines each hold distinct importance in the field of immunization, catering to different aspects of disease prevention. While multivalent vaccines are more commonly used in many vaccination programs, both types play crucial roles in safeguarding public health. Multivalent vaccines are designed to protect against multiple diseases or strains within a single vaccine shot. They offer the advantage of convenience, reducing the number of vaccinations individuals need to receive. Examples of widely used multivalent vaccines include those for measles, mumps, rubella (MMR), and the combination vaccines for various strains of influenza. These vaccines simplify vaccination schedules, improve compliance, and help control the spread of multiple diseases efficiently. On the other hand, monovalent vaccines are specifically tailored to protect against a single disease or pathogen. They are valuable when dealing with diseases where the pathogen exhibits significant variations, or when targeting a specific health threat, such as a new emerging infectious disease or a disease with a complex structure. Monovalent vaccines offer precision in immunization, ensuring focused protection against a particular threat. The choice between multivalent and monovalent vaccines depends on several factors, including the epidemiology of the disease, the population's susceptibility, and the availability of effective vaccines. Both types contribute to the success of vaccination programs and the reduction of disease burden. Multivalent vaccines provide broad protection, while monovalent vaccines offer tailored defense when needed. Considered in this report: • Geography: Spain • Historic year: 2017 • Base year: 2022 • Estimated year: 2023 • Forecast year: 2028 Aspects covered in this report: • Spain Vaccine Market with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Technology: • Conjugate vaccines • Inactivated & Subunit vaccines • Live Attenuated vaccines • Recombinant vaccines • Toxoid vaccines

By Route of Administration: • Intramuscular and Subcutaneous Administration • Oral Administration • Others (Intradermal Administration, Nasal Administration, Intravenous Administration, Transdermal Patches, Oral-Mucosal Vaccines, Microneedle Patches, Jet Injectors, Intraperitoneal Administration, Intranasal Droplets, etc.) By End-User: • Paediatric Vaccines • Adult Vaccines By End-User: • Pneumococcal diseases • Cancer • Influenza • Rotavirus • Diphtheria, Pertussis, and Tetanus (DTP) • Human Papilloma Virus (HPV) • Shingles • Meningococcal diseases • Hepatitis • Varicella (Chicken Pox) • Mumps • Others (Rabies, Dengue, Typhoid, Polio, Japanese Encephalitis, Rubella, Herpes Zoster, Tuberculosis, Yellow Fever, etc.) By Type: • Multivalent vaccines • Monovalent vaccines By Distribution Channel: • Hospital Pharmacy • Retail Pharmacy • Institutional Sales • Others (Specialized Clinics, Community Health Centers, Telemedicine and Online Pharmacies, Nonprofit Organizations, Government Distribution Programs, etc.) The approach of the report: This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources. Intended audience: This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Vaccine market, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.